Threshold Pharmaceuticals (THLD) PT Raised to $15 at Piper Jaffray

Piper Jaffray analyst Charles Duncan reiterated an Overweight rating and boosted his price target on Threshold Pharmaceuticals (NASDAQ: THLD) to $15.00 (from $13.00) saying a Hypoxia driven pipeline could emerge in 2015.

Duncan commented, "We recently caught up with Threshold because we believe 2015 could prove transformational for the company. Due to 2015 likely yielding multiple pivotal trial readouts and increased visibility on a wholly-owned but as yet under the radar-screen program that could take a run at higher profile TKi lung cancer programs, we would now include THLD as a top-pick small cap, under-discovered OncoInnovator. The key events of note in 2015 may be data (event driven) from the Phase IIIs for TH-302 in soft tissue sarcoma (STS) and pancreatic cancer. These are likely YE15 or early-'16 events but recent data in STS enhance our conviction that the study design could result in approvable and clinically significant benefit of 25-35% increased OS in this SPA-backed trial."

For an analyst ratings summary and ratings history on Threshold Pharmaceuticals click here. For more ratings news on Threshold Pharmaceuticals click here.

Shares of Threshold Pharmaceuticals closed at $3.52 yesterday.

You May Also Be Interested In

• HashiCorp Inc (HCP) PT Raised to $32 at BofA Securities
• East West Bancorp (EWBC) PT Raised to $90 at BofA Securities
• Gulf Keystone Petroleum Ltd (GKP:LN) PT Raised to GBP1.75 at Canaccord Genuity